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Critical design issues in the targeted molecular
imaging of cell surface receptors
Neil Sim and David Parker*
The imaging of cell-surface receptors can be achieved using several methods, including single photon
emission tomography (SPECT) positron emission tomography (PET), optical imaging and magnetic
resonance imaging (MRI). The application of targeted MRI contrast agents is particularly well-suited to
this task, provided that the agents reach the desired site eﬃciently and selectively. In addition, they
should bind reversibly to the cell-surface receptor and give rise to a large change in cellular relaxation
rate, in competition with binding to the natural substrate. Such approaches oﬀer promise in the
molecular imaging of neurotransmission in the brain, using conjugates that selectively target dopamine
or glutamate receptor sub-types. Strategies based on the use of competitive antagonist vectors oﬀer
particular scope, as such conjugates are generally not taken into the target cell following cell surface
receptor binding, in contrast to the use of MRI contrast agents based on agonists that tend to be
internalised quickly or are designed to target intracellular sites.
Key learning points
1. To target a cell-surface receptor, both cell specificity and receptor selectivity required.
2. Address systems that are not internalized to reduce the risk of toxicity.
3. Use a competitive antagonist as a targeting vector, not an agonist, to avoid internalisation.
4. Avoid non-specific binding: consider competitive binding of the ligand moiety and at the metal centre.
5. For MRI, use a Gd probe in which relaxivity changes are not quenched by slow exchange kinetics and in which probe binding is reversible.
1. Introduction
Molecular imaging has been defined as the non-invasive visualisa-
tion of biochemical events at the molecular level within cells,
tissues or whole-bodied specimens.1 It is one of the most rapidly
expanding areas of scientific and medical research. Over the past
twenty years, eﬀorts have been made to identify specific molecular
events in vivo, leading to the design and development of targeted
probes or contrast agents, to provide or enhance image contrast.
Labelled antibodies, peptides, proteins and small molecules have
each been employed in this manner, but it is often diﬃcult to
obtain suﬃcient signal intensity change, due to the relatively low
probe-target to background ratio. Indeed, it is often the case that
the target of interest is present in relatively low concentrations.
Such a situation may arise for a cell-surface receptor that is
expressed selectively in a particular cell type, or over-expressed in
certain disease states. Nevertheless, these issues can be overcome
by improving the contrast agent’s pharmacokinetics and aﬃnity,
coupled with the use of rapid and sensitive, high-resolution
imaging techniques.
The selection of a particular molecular imaging modality is
highly dependent upon the biochemical process to be examined
and the nature of the information needed. The key design issues
that need to be considered include: the spatial resolution
required; the sensitivity needed i.e. the likely concentration of
the target; whether dynamic information is to be obtained; whether
whole body or regional imaging is required; the temporal resolution
and the depth of penetration. By carefully considering each of these
issues, it is possible to select the best imaging technique to use,
(Fig. 1 and Table 1)
This aim of this tutorial review article is to assess critically the
progress made in the design and study of molecular imaging
agents that target cell surface receptors. The review focuses on
molecular MRI contrast agents based on Gd(III) conjugates, rather
than conjugates of metal oxide or semiconductor particles. Whilst
it is appreciated that the pharmacokinetics of a molecular
imaging agent will largely determine the ratio of specific/non-
specific binding in vivo and that the key issues of the toxicity,
administration and delivery of the agent must be assessed in
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defining the potential for clinical translation, this review addresses
the key chemical principles that must be considered first, in order to
design an eﬀective molecular imaging agent for future evaluation.
Particular emphasis is given to imaging agents that target cell-
surface receptors, comparing internalised versus non-internalised
systems. Their merits are assessed with respect to those agents
targeting a receptor found within the cell, and those that are rapidly
internalized.
2. Receptor-targeted Gd(III)-MR
contrast agents
There are numerous examples of extracellular Gd(III) contrast
agents that have been designed to report upon local changes in
pH, metal ion concentration and enzyme activity.2–4 Details of
examples have also been described of contrast agents targeted
towards abundant blood pool proteins, such as human serum
albumin (HSA) or fibrin.5 However, this review will examine the
contrast agents that have been designed to change their relaxivity-
defined as the increment of the water proton relaxation rate per
unit complex concentration-following association with cell-surface
receptors, comparing where appropriate with systems involving an
intracellular receptor.
The fact that there are only a few reports of these contrast
agents can be ascribed to the low sensitivity of the MRI method.
Following administration of a Gd(III) complex, it has been
suggested that there needs to be a 5 mM local Gd(III) concen-
tration in order to observe a 5% change in the water relaxation
rate, R1, for a contrast agent which possesses a relaxivity of
5 mM1 s1.6 This situation corresponds to about 107 Gd ions
per cell, setting an approximate limit to the receptor density
required in order to measure an observable change on contrast
agent binding. Such thinking makes it diﬃcult to imagine how
to image the majority of cell surface receptors using MRI, as
they are believed to be present at concentrations in the 10 to
100 nanomolar range. However, receptor density is likely to be
heterogeneous, with high local concentrations and for a high
aﬃnity targeted gadolinium complex, the rate of dissociation
from the receptor site will be slow and may be of the order of
1 s1, if the forward rate of association is 107 s1, i.e. when
Kd = 0.1 mM. This means that the timescale of the imaging
experiment (one or two seconds) is of the same order as the
lifetime of the bound complex, enhancing the intrinsic sensitivity
of the experiment.7 Furthermore, if the relaxivity of the receptor
bound complex increases substantially compared to the unbound
complex, the intrinsic sensitivity of the experiment is also
increased. Such relaxivity enhancement is usually limited to the
low field range of 0.4 to 1.5 Tesla (T), where rotational dynamics
plays the major role in determining relaxivity for a Gd(III) contrast
agent, when water exchange is fast (i.e.B107 s1).4,5 Happily, this
coincides with the magnetic field strengths of the older more
common human imaging systems that operate at 1.5 T. The
relaxivity enhancement reaches a maximum typically between
1 and 1.5 T, but drops quite rapidly beyond 1.5 T since
rotational dynamics are no longer dominant. However, image
resolution is greater at these higher magnetic fields (B) and
so is sensitivity, as signal intensity in a magnetic resonance
experiment increases as B3/2.
2.1 Intracellular receptor-targeted contrast agents
First, it is necessary to assess the prior work that has been
undertaken where the target site is found mainly within the
cell, for which issues of cell permeability and retention require
very careful consideration. Cancer cells are known to over-
express a variety of receptors that are present on or in healthy
cells. The higher concentration of these receptors allows
targeted-contrast agents to overcome the inherent low sensitivity
of MRI. The progesterone receptor (PR) is a useful marker for cancer
progression and is frequently used to predict patient prognosis.
Historically, progesterone receptor levels are determined from
in vitro immunohistochemistry assays of patient samples
gained by invasive biopsies. However, Meade and co-workers
Fig. 1 The major pre-clinical and clinical imaging modalities: CT = X-ray
computed tomography; PET = positron emission tomography; SPECT =
single photon emission computed tomography; MRI/MRS = magnetic
resonance imaging/spectroscopy, (adapted from the original1).
Table 1 Resolution, sensitivity and depth of penetration of the major clinical imaging modalitiesa 1
Modality Temporal resolution Spatial resolution Depth penetration Sensitivity/M
X-ray CT min 0.5–1 mm Unlimited ND
MRI min 0.25 to 1 mm Limited by magnet bore 103–105
PET s–min 5–10 mm Unlimited 1011–1012
SPECT min 8–10 mm Unlimited 1010–1011
Ultra-sound s–min 1–2 mm A few cm ND
Optical fluorescence imaging s–min 2–3 mm o1 cm 109–1012
Optical bioluminescence imaging s–min 3–5 mm 1–2 cm 1015–1017
Photoacoustic imaging s–min 10 mm–1 mm 6 mm–3 cm ND
a ND: not determined.
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have described the development of progesterone receptor-targeted
MRI contrast agents, which could potentially report the degree of
cancer progression.
Their initial complex, [Gd.L1.0] (Scheme 1), induced a 40%
enhancement in the water proton longitudinal relaxation rate,
R1, upon incubation with progesterone receptor positive cells,
notwithstanding a relatively weak aﬃnity for the progesterone
receptor (IC50 = 1.91 mM).
8 In order to increase relaxation rate
enhancement, three further complexes were synthesised
(Scheme 1), in an eﬀort to maximise intracellular accumulation
and progesterone receptor aﬃnity. The eﬀect of charge on the
complex lipophilicity and cell permeability was assessed, along
with the eﬀect of the length of the spacer unit separating the
progesterone motif and Gd(III) chelate.9
In order to increase intracellular accumulation, it was reasoned
that a complex with a more positive logP value would assist in
enhancing cell permeability. Therefore, the neutral complexes
[Gd.L1.1] and [Gd.L1.2] were selected as the lead complexes. The
length and nature of the spacer group also had an eﬀect on the
aﬃnity for the progesterone receptor. Surprisingly, [Gd.L1.1] with no
spacer exhibited the largest aﬃnity for the progesterone receptor,
suggesting the possibility of a favourable interaction between the
hydrophilic Gd(III) chelate and the receptor binding site. However,
each complex exhibited an approximately 100-fold increase in
progesterone receptor aﬃnity over [Gd.L1.0], with IC50 values in
the nanomolar range. Of the four complexes, [Gd.L1.2] showed the
best charge and spacer properties and was selected for further
evaluation.9
The complex, [Gd.L1.2], was internalised in both progester-
one receptor positive and negative cells, with the progesterone
receptor positive cells exhibiting twice the accumulation of the
complex over a 24 hour period, as compared to the progester-
one negative cells. Furthermore, the non-targeted contrast
agent, [Gd.DO3A], exhibited a negligible accumulation in both
progesterone positive and negative cells, over the same time
period. Such behaviour suggested that [Gd.L1.2] is retained
longer in the progesterone receptor positive cells, by virtue of
its interaction with the intracellular receptor. The non-specific
uptake of [Gd.L1.2] into progesterone receptor negative cells was
attributed to the higher hydrophobicity and cell permeability of
the complex, with respect to [Gd.DO3A].10 Retention of [Gd.L1.2]
in the uterus, ovaries and mammary glands over a 24 h period
demonstrated the ability of the contrast agent to target progesterone
receptor rich tissue. Importantly, [Gd.L1.2] did not accumulate in the
abdominal tissue or fat. Finally, [Gd.L1.2] was shown to enhance the
contrast of progesterone receptor positive tumours in the presence of
progesterone receptor negative tumours in vivo. Irrespective of
the mode of administration (subcutaneous vs. intra-peritoneal), a
significant diﬀerence in the T1-weightedMR images between the two
tumours was evident, 2 to 6 h post injection (Fig. 2).10
Despite the relative successes of [Gd.L1.2], it should be noted
that this contrast agent is based on an N-alkyl–DO3A system.
Such systems are likely to bind to protein non-specifically11 via
coordination at the Gd centre. Indeed, approximately 30% of
[Gd.L1.2] was found to reside in the membrane and was there-
fore unavailable to interact with the progesterone receptor.
Alternatively, the complex may bind reversibly to endogenous
anions (e.g. bicarbonate), leading to displacement of the coordinated
water molecule. This effect will tend to reduce the relaxivity gain
observed upon receptor binding. Furthermore, the impact of non-
specific protein binding on cellular uptake was not assessed, which
may be a reason for their relatively poor specificity of cellular uptake
(only 2 :1). Finally, the poor water solubility and intracellular uptake
of [Gd.L1.2] resulted in significant acute toxicity, possibly due to
gadolinium retention that could be associated with premature
dissociation of the Gd ion from its ligand.
In an attempt to reduce the toxicity associated with [Gd.L1.2],
the lipophilicity of the complex was adjusted through modifica-
tion of the linker unit.12 As expected, no change in progester-
one receptor aﬃnity was observed. However, an increase in
cellular uptake of [Gd.L1.3] was achieved in progesterone positive
tumours; 90% of the complex was found to localise within the cell,
apparently in the cytoplasm, where one form of the progesterone
receptor is located. Contrast-to-noise ratios in T1-weighted MR
measurements of [Gd.L1.3] were comparable to those for [Gd.L1.2],
but the increased water solubility resulted in an increase in cell
viability.
Notwithstanding these improvements, [Gd.L1.3] is based on
a mono-amide–DO3A system. Such complexes with amide
carbonyl coordination giving a 5-ring chelate, have inherently
Scheme 1 Structures of progesterone receptor-targeted contrast agents.8–10
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slower water exchange rates (kexB 10
6 s1) and so the relaxivity
gain at fields between 1.5 to 7 T, associated with modulation of
the effective rotational correlation time, is quenched. Further-
more, the receptor-targeting moiety is attached through an
ester linkage, which is very likely to be susceptible to hydrolysis
by extracellular esterases. A chemical linkage that is less prone to
metabolic transformationmight give increased cellular retention
in progesterone positive tumours, leading to an enhancement in
signal contrast.
2.2 Cell surface receptor targeted contrast agents
In 1995, a seminal paper13 described how Gd-DTPA chelates
conjugated to polylysine, loaded onto DNA containing transferrin,
were able to label cells expressing the cell-surface transferrin
receptor. A large enhancement in the T1-weighted MR image
contrast ensued, compared to untreated cells. Furthermore, cells
treated simultaneously with the Gd-DTPA loaded DNA-transferrin
conjugate and also iron-loaded transferrin resulted in a negligible
enhancement in T1-weighted MR contrast, due to competition for
the receptor site. This demonstrated that the internalisation of the
contrast agent was mediated by the cell surface receptor.13
Folate is an essential vitamin for cells and binds with high
aﬃnity to the folate receptor present on the cell surface. Upon
binding of folate, the folate receptor–ligand conjugate undergoes
receptor-mediated endocytosis leading to folate internalization.
Following release of the folate, the receptor returns to the cell
surface ready for the next ligand to bind.
In systems targeting folate receptors, most reported work
has used a derivative of folate itself. Such imaging agents are
then likely to be quickly internalized, increasing the local
concentration of the imaging agent in the desired cell type.
There are several examples in the literature of polymeric, high
molecular weight contrast agents that target the folate receptor,
as this receptor can be expressed in high concentration, e.g. in
certain ovarian cell lines.14–16 One example of a low molecular
weight complex was reported by Kalber and co-workers,17 who
synthesised a contrast agent by conjugation of folic acid to a
[mono-amide-GdDO3A] chelate, separated by an ethylene glycol
spacer (Fig. 3). Inductively coupled mass spectrometry (ICP-MS)
measurements showed that the complex [Gd.L1.4] was internalised
readily by folate receptor positive (FR+) cells after 1 hour, withmore
than double the accumulation than in folate receptor negative
(FR) cells. Although tumour perfusion studies were apparently
not undertaken, the presence of free folic acid in the cell growth
medium as a competitor resulted in a reduction in uptake of
[Gd.L1.4] into FR+ cells, consistent with receptor-mediated inter-
nalisation. This study however, was carried out in vitro but was not
seemingly undertaken in vivo, where it has more relevance.
Despite confirmation of cellular labelling by ICP-MSmeasure-
ments, there was no increase in cellular relaxation rate in vitro,
after incubation of [Gd.L1.4]. On the other hand, when [Gd.L1.4]
was administered to nude mice bearing a folate receptor-positive
tumour xenograft, up to a 50% enhancement in R1 was observed
over a 14 hour period, resulting in increased T1-weighted MR
contrast (Fig. 3). In comparison, no increase in R1 was reported for
tumour xenografts bearing folate receptor-negative cells, nor when
the non-targeted agent, [Gd.DOTA], was used. In this case, it was
suggested that the non-targeted [Gd.DOTA] was rapidly washed
out of the tumour, prior to the 2 h observation point.
The contrasting results obtained in vitro and in vivo results
are worthy of consideration. Inherently, there are diﬀerences in
delivery and transport in the two sets of studies; in the former
case, the cells are in direct contact with the complex solution for 2,
4 and 14 h, whereas in the latter these times are the observation
points of a dynamic flowing system. The relative degree of inter-
nalization and tumour wash-out are probably most significant.
Indeed, the authors suggest a significant degree of cellular
variation in folate receptor expression as one reason for the
contrasting behaviour. This plausible assumption can be assessed by
immunofluorescence staining experiments, although it is diﬃcult to
determine the real mechanism by which R1 increases in vivo. The
intracellular fate of the complex is key. Once the complex is
bound to the folate receptor, internalisation is likely to be fast via
receptor-mediated endocytosis, resulting in the contrast agent
Fig. 2 T1-weighted MR images and contrast-to-noise plots (7 T) of mice bearing a tumour xenograft intraperitoneally injected with [Gd.DO3A] or
[Gd.L1.2]. A significant contrast enhancement is observed in both progesterone receptor positive and negative tumours over a 6 h period, when injected
with [Gd.L1.2].10
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residing inside an endosome. If it escapes from this compartment, it
could bind non-specifically to intracellular proteins, modulating tR,
and increasing R1. However, the expected relaxivity gain in vitro could
be quenched if the contrast agent is trapped in a sub-cellular vesicle/
endosome after internalisation, limiting the rate of water exchange
on/oﬀ Gd, kex.
18 Whatever the reasons for the discrepancies, the
design of the complex could also limit the expected relaxivity gain.
Mono-amide Gd(III) 5-ring chelates possess rather slow water
exchange rates (around 106 s1 at 298 K), quenching the relaxation
enhancement that can arise from non-covalent binding to the more
slowly rotating macromolecule.
A further example of a folate receptor-targeted contrast
agent emanated from work in Durham in 2001.19 In a similar
approach, folic acid was conjugated to a Gd(III) chelate. However,
the ligand used to encapsulate the Gd(III) ion was a tetra-carboxy-
substituted DOTA, giving the complex overall negative charge
(Scheme 2).
In work carried out in vitro only, this complex was found to
exhibit an 80% increase in R1 in the presence of folate binding
protein (FBP), but a negligible increase in the presence of the
model protein serum albumin (pH 7, 60 MHz, 310 K). The
complex had a fast water exchange rate (kex B 10
7 s1). Coupled
with the overall negative charge that hinders non-specific binding,
e.g. to serum albumin, the large R1 enhancement in the presence
of FBP can be rationalised.
The formyl peptide receptors (FPRs) are a class of G-protein-
coupled receptors present on the surface of neutrophils. Their
main function is to mediate migration of neutrophils to a site of
injury causing an inflammatory response. Long and co-workers20
synthesized an FPR-1-targeted MR contrast agent based on the
hexapeptide, cFLFLFK, known to be an antagonist for this
receptor. Conjugation of the peptide fragment to the Gd(III)
chelate through the N-terminal lysine residue did not disrupt
the aﬃnity of the antagonist towards the receptor, with the
apparent binding aﬃnity only slightly decreasing (Kd = 4.5 vs.
2 nM for [Gd.L1.5] and native peptide, respectively).
The complex [Gd.L1.5] was intravenously administered to
mice (1 mmol kg1), which had been pre-injected with an
inflammatory agent for 24 h. Upon administration, a signifi-
cant increase in T1-weighted MR contrast ensued and was
visible for up to 80 min. post injection at the site of inflamma-
tion (Fig. 4). The non-targeted complex, [Gd.DOTA], was used
as a control. It gave rise to an initial increase in T1-weighted
contrast after 1 minute, but was undetectable 80 min. post
injection (Fig. 4). It is a more hydrophilic agent of lower
molecular volume than [Gd.L1.5] that is expected to clear more
quickly from inflamed tissue, and therefore has limited utility
in comparative studies. The authors attribute the diﬀerence in
time-dependent, T1-weighted contrast to specific targeting and
binding of [Gd.L1.5] to the neutrophils’ FPR-1 receptor, prolonging
the contrast agent’s lifetime at the site of inflammation.
Of the examples of receptor-targeted MR contrast agents in
the literature, there are very few that are targeted towards cell
surface receptors. Dopamine is an abundant neurotransmitter
in the central nervous system and mediates its eﬀects through
metabotropic dopamine receptors. The dopaminergic system
is related to many neurological and psychological disorders.Scheme 2 Structure of an anionic g-folate-[Gd-gDOTA] conjugate.19
Fig. 3 Top: structure of folate receptor-targeted contrast agent, [Gd.L1.4]; below: T1-weighted MR images of a folate receptor positive tumour
xenograft: (a) pre-administration; (b) 2 h post and (c) 14 h post-administration of [Gd.L1.4].17
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The D2/D3 dopamine receptors are the primary sites targeted
by anti-Parkinsonism and anti-psychotic drugs.
Cohen and co-workers21,22 have synthesised a small series of
D2/D3 receptor-targeted MR contrast agents based on an
N-alkyl–DO3A system conjugated to modified dopamine receptor
ligands (Scheme 3). In an inhibition assay, complex [Gd.L1.6] was
shown to possess a large decrease in binding affinity for the
dopamine D2-receptor, relative to the radiolabeled ligand, with
an IC50 for [Gd.L
1.6] of approximately 10 mM. The decrease in
affinity reflects the large modification made to the spiperone
ligand, inhibiting receptor binding. In an attempt to increase
receptor affinity, further complexes were synthesised, reducing the
number of structural modifications to the spiperone ligand and
varying the length and nature of spacer (Table 2). An increase in D2
receptor binding affinity was found for [Gd.L1.7–1.8], demonstrating
the need for the entire ligand moiety to be present in order to
maintain affinity.
Notwithstanding the demonstration of the ability of these
conjugates to bind at the dopamine D2 receptor, there is a
significant amount of work missing to fully characterise
[Gd.L1.6–1.9] as dopamine-receptor targeted contrast agents.
Firstly, there are no in vitro studies that demonstrate a change
in relaxivity of these complexes upon binding to the dopamine
receptor. The degree of relaxivity enhancement upon receptor
binding would be limited due to the choice of the Gd(III)
chelate, since N-alkyl–DO3A systems are likely to bind non-
specifically to endogenous protein or anions11 leading to dis-
placement of the coordinated water molecule, and a reduction
of the relaxivity gain. Furthermore, specifically in [Gd.L1.8–1.9],
the ligand moiety is positioned at a considerable distance from
the Gd(III) chelate. Although the presence of this longer linker
should tend not to inhibit the affinity of the complex for the
receptor based on steric arguments, it could limit the relaxivity
gain upon receptor binding. The expected increase in R1 is
modulated by the rotational correlation time, tR. Therefore, the
long spacer in these systems will induce independent motion of
the slowly tumbling macromolecule and the Gd(III) chelate,
resulting in only a small relaxivity enhancement on receptor
binding.
Scheme 3 Structures of potential dopamine receptor-targeted MR contrast agents based on heptadentate ligands for the Gd ion (indicative hydration
states at Gd are suggested, but were not determined).
Table 2 Comparative binding aﬃnities and relaxivity values (9.4 T, H2O/
D2O 1 : 1, 298 K) of dopamine receptor-targeted contrast agents
21,22
[Gd.L1.6] [Gd.L1.7] [Gd.L1.8] [Gd.L1.9]
IC50/M 1  105 5  109 1  108 1  106
r1/mM
1 s1 5.9 5.5 7.8 ND
Fig. 4 T1-weightedMR images of amouse brain: (A) pre-injection; (B) 80min.
post-injection of [Gd.L1.5]; in comparison, (C) pre-injection; (D) 1 min. post;
(E) 80 min. post-injection of the control [Gd.DOTA].20
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3. Molecular imaging of glutamate
receptors
Metabotropic glutamate receptors (mGluRs) are part of the
glutamate neurotransmitter system. They are G-protein coupled
receptors with a large extracellular N-terminus in which the
orthosteric glutamate binding site is located. Eight subtypes
have been characterised that are divided into three subgroups,
depending on their distribution, amino acid sequence homology
and the types of G-protein to which they are coupled. Group I
consists of the mGluR subtypes 1 and 5, and their activation
leads to calcium release from intracellular stores into the cytosol
and subsequently to the activation of a variety of intracellular
signalling molecules. The other two groups II (mGluR2,3) and III
(mGluR4,6,7,8) are coupled to Gi/o-proteins and their activation
results in a decreased intracellular formation of the secondary
messenger, cyclic adenosine monophosphate (cAMP). Both
group II and III receptors are mainly found on pre-synaptic
terminals, whereas mGluR1 and mGluR5 are mostly localised on
postsynaptic neurons (i.e. dendritic spines). Notably, the mGluR5
and mGluR3 receptors are expressed and fully functional on
astrocytes.
The mGluR5 receptor itself has several physiological roles in
normal brain function. These receptors are widely distributed
throughout the brain, reflecting functions such as emotion and
motivational processes as well as diﬀering aspects of cognitive
function. The extensive roles of the mGluR5 makes it a key
target for therapeutic intervention and a number of small
molecules have been described that modulate the function of
mGluR5.
23–25 Numerous applications up to advanced clinical
trials have been described.26 Examples for possible therapeutic
purposes of mGluR5-modulators, include their use as antide-
pressant-/anxiolytic drugs (e.g. in the case of otherwise treat-
ment resistant depression) as revealed in preclinical models.27
Other examples of possible therapeutic uses of functional
mGluR5-modulators include treatment of schizophrenia
28 and
neurodegenerative disorders, such as Parkinson’s disease,29
and the application of mGluR5-antagonists as treatment stra-
tegies for autism.30 There have been several molecular imaging
approaches used to aid the visualisation of glutamate receptors.
Recent examples have been reported relating to the use of PET/
SPECT, optical and magnetic resonance methods for imaging.
3.1 PET and SPECT radiotracers for glutamate receptors
Both the PET and SPECT techniques possess very high sensi-
tivity (1011 – 1012 M) and can be used to image whole bodied
live subjects.1 There have been several reports concerning the
synthesis and application of PET and SPECT tracers for gluta-
mate receptors.31 The majority of these tracers are derived from
well-known ligands (agonists) of glutamate receptors, with the
incorporation of either an 18F/11C radiolabel for PET tracers
and 123I/111In labels for SPECT. The introduction of an 11C label
into a structure and the replacement of 1H by 19F offers a
minimal perturbation to the structure, and hence is most likely
not to change the behaviour of the imaging agent with respect
to the parent ligand. Of the examples in the literature, the most
well-characterised PET tracer for mGluR5 receptors is [
18F]-SP203
(Scheme 4).32 This tracer was synthesised in a high radiochemical
yield via nucleophilic substitution of the bromomethyl analogue
with [18F]-KF,33 resulting in a ligand with an extremely high affinity
(IC50 = 0.036 nM) and selectivity for mGluR5. Rapid uptake into the
brain of rhesus monkeys was observed, with the radioactivity
residing in mGluR5-rich regions. Although a moderate amount of
activity accumulated in the skull during the in vivo experiments
with monkeys,34 this was not observed in a pilot study with seven
healthy human subjects.
The N-methyl-D-aspartate receptor (or NMDAR) is an ionotropic
glutamate receptor that is involved in controlling synaptic plasticity
and memory function. Uniquely, it requires co-activation by gluta-
mate and either glycine or D-serine. For radiotracers synthesised to
target NMDA receptors, the SPECT ligand, [123I]-CNS 1261
(Scheme 4) has shown the most potential.35 In human experiments,
this tracer showed high distribution volumes in regions consistent
with high NMDA receptor concentrations. Specific binding to the
NMDA receptor was confirmed in a competition experiment with
ketamine, but due to high degree of non-specific binding, the ability
to detect small changes in receptor availability was limited.
Whilst there has been some success in the development of
radiotracers for PET and SPECT imaging of glutamate receptors,
there are many limitations associated with these methods. First,
the intrinsic resolution of these techniques is low, (1–10 mm),
which limits the ability to observe small changes at a receptor
site. Furthermore, these methods require the efficient chemical
synthesis of suitable radiolabelled tracers. Although the installa-
tion of a radiolabelled nucleus is probably a lot less perturbing to
the biochemical activity of the ligand with respect to conjugation
of a fluorophore or Gd-chelate to the ligand, this approach
usually requires a cyclotron nearby to generate the short-lived
radionuclide. The isotope must be introduced into the substrate
in a high yielding and fast radiolabelling reaction.
3.2 Optical imaging of glutamate receptors
Similar to PET and SPECT, optical imaging is endowed with
excellent sensitivity (109–1012 M) and can be used to image
bio-molecules, which are present in lower concentrations, such
as the ionotropic glutamate receptors. Fluorescently labelled
ligands offer advantages over radiolabelled analogues, as they
are generally safer and easier to handle. However, the major
limitation of optical imaging is the poor tissue penetration of
photons in the range of 400–900 nm; penetration depths of no
more than a few mm only are possible, due to co-absorption
and light scattering.
Scheme 4 Structures of PET and SPECT agents for glutamate receptor
imaging.
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Chambers and co-workers have developed a four-component
molecular probe for visualisation of AMPA receptors.36 The
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
(AMPA) is a non-NMDA-type ionotropic transmembrane receptor for
glutamate. It mediates fast synaptic transmission in the central
nervous system. The design of the probe (Fig. 5) was based on a
polyamine ligand (known to bind in the AMPA channel), conjugated
to a cyanine dye fluorescent reporter, via a photo-cleavable linker.
The molecule also bears an electrophilic acrylamide moiety, which
can undergo reaction with a nucleophilic partner, such as an amino
acid side chain present on the AMPA receptor, to anchor the probe
to the receptor (Fig. 5). The probe was found to block functional
AMPA receptors in electrophysiology experiments. Removal of
the polyamine block restored the receptor to its native state,
after irradiation with 380 nm light.
When cells were treated with the Cy3 probe for 2 mins and
then continuously perfused with fresh buﬀer, fluorescence was
observed around the synaptic junction, consistent with the
expected distribution of AMPA receptors (Fig. 6). The fluorescence
intensity was time-dependent, decreasing rapidly over a seven
minute period (Fig. 6). In comparison, incubation of the Cy3
reporter lacking the targeting ligand gave rise to no cellular
localisation in microscopy studies, suggesting that the acrylamide
moiety does not react promiscuously with any nucleophile.36
Despite the visualisation of AMPA receptors, there are some
limitations to this work. It is not clear whether or not imaging
is performed after photo-dissociation of the polyamine ligand,
and whether the Cy3 unit directly bound to the AMPA receptor
is being visualised. The fact that the fluorescence decreases
over time suggests that the positively charged polyamine is also
labelling the plasma membrane non-specifically, and can then
be washed out over time. It is unclear as to whether the probe is
selective for labelling AMPA receptors, as all iGluRs possess a
polyamine-binding site.
Another example exploiting the use of fluorescently labelled
channel blockers is from Strømgaard and co-workers,37 who
systematically replaced the aromatic head-group of polyamine
iGluR channel blockers with fluorescent labels of varying size.
It was found that as the size of the fluorophore increased, the
compounds aﬃnity for the AMPA and NMDA receptor decreased.
Furthermore, the size of the fluorophore had an impact on the
selectivity of the probes toward diﬀerent receptors but, in general, a
higher aﬃnity for the AMPA receptor was observed.
The most promising BODIPY probe (Fig. 7) was used in
cellular staining experiments of NMDA receptors transfected
with the red fluorescent protein, mCherry. Upon incubation of
the BODIPY probe, a considerable degree of non-specific binding
was observed due to interaction of the positively charged polyamine
with the plasma membrane. However, following a continuous five
minute wash period, the non-specific staining was removed to
reveal punctate fluorescence, overlapping with mCherry emission
along the dendrites (Fig. 7). In contrast, cells treated with a similar
compound but with a much weaker aﬃnity for the NMDA receptor
showed no cellular localisation, after the 5 min. wash period.37
Recently, Perrio and co-workers have synthesised three
series of NMDA receptor NR2B subunit specific optical imaging
probes by conjugation of fluorescein to derivatives of the non-
competitive antagonist, ifenprodil.38,39 The point of attachment
and length of spacer unit connecting the fluorophore to the ligand
moiety was found to strongly dictate probe aﬃnity towards the
NMDA receptor. By measuring Ca2+ influx transients in a compet-
itive assay, optimal aﬃnity was demonstrated when conjugation
Fig. 5 Schematic representation of the putative mechanism of action of the Cy3 probe.36
Fig. 6 (a) Fluorescent images of neurons 30 seconds after incubation of Cy3 probe. (b) Magnified region after 5 minutes of washing with buﬀer.
(c) Quantitative analysis showing a decrease in fluorescence intensity from the neuronal cells over a short period of time.36
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occurred through modification of the benzylic hydroxyl group of
ifenprodril. Generally, a longer spacer increased aﬃnity for the
NR2B subunit, although IC50 values were approximately 6-fold
higher as compared to ifenprodil. Other pharmacological proper-
ties, such as sub-unit selectivity and neuroprotective eﬀects were
not compromised by the conjugation of the fluorophore.
When neuronal cells expressing Ds-Red labelled NMDA
receptors were treated with fluorescein-ifenprodil, a punctate
green fluorescence was observed from the fluorescein moiety
(Fig. 8). This fluorescence image corresponded well with the red
fluorescence from the genetically labelled NMDA receptors,
demonstrating co-localisation of fluorescein-ifenprodil at the
NMDA receptor (Fig. 8). Furthermore, when cells were pre-treated
with ifenprodil and then loaded with fluorescein-ifenprodil, no
fluorescence was observed, suggesting fluorescein-ifenprodil
localises and binds in the same position on NMDA receptors
as the native ligand (Fig. 8). Despite the increased sensitivity
and resolution associated with optical imaging methods, this
technique is limited by light scattering and absorbance in soft
tissue, and has a low eﬀective imaging depth of the order of
10 mm or so.
3.3 Gd(III)-MRI contrast agents for glutamate receptors
For brain imaging, more detailed spatio-temporal information is
required about the chemical processes associated with neuro-
transmission and their relationship to cognitive behaviour,
learning and disease status and progression. The utility of MRI
is improved by the use of contrast agents, especially those that
enhance specificity and sensitivity by targeting certain regions of
interest, or that allow the monitoring of changes in chemical
composition as a function of neural activity. This rationale has
driven the recent development of agents that selectively target the
various glutamate receptors that are found in high abundance on
the cell surface of astrocytes.7,40,41 These responsive contrast agents
must bind selectively and reversibly to the receptor, and not be
internalized, so that changes in local contrast agent levels can be
modulated following the extracellular glutamate bursts that peri-
odically occur following a stimulus.
The release of glutamate from a pre-synaptic cell takes place
over a period of a few milliseconds and should lead to the
displacement of a contrast agent that is already bound to the
cell surface receptor. MRI has been hypothesised to be able to
monitor the restoration to equilibrium that occurs over a
period of a second or two.7 As the glutamate levels drop and
the contrast agent competes for binding to the receptor,
glutamate is displaced, leading to local signal intensity
enhancement once more. Such a perturbational approach
requires that the contrast agent is bound reversibly and with
relatively high aﬃnity to the target site, with minimal non-
specific binding. For these reasons, conjugates of gadolinium
contrast agents with established competitive antagonists for
glutamate receptors have been examined. When bound to the
receptor site, the rotational dynamics and second sphere of
hydration around the gadolinium moiety are perturbed, leading
to relaxivity enhancement and increased image intensity.
Fig. 7 Above: structure of iGluR-targeted BODIPY probe; below: confocal microscopy images of neurons expressing mCherry-tagged NMDA receptors
(red fluorescence). Cells were treated for 2 min. with 50 nM of BODIPY probe (green fluorescence) and then imaged at beginning of washing stage (T0)
and following five minutes continuous washing (T5).
37
Fig. 8 Above: structure of fluorescein-ifenprodil; below: confocal micro-
scopy images of Ds-Red labelled NMDA receptors (red fluorescence):
(A) Ds-Red emission; (B) visualisation of fluorescein emission after incuba-
tion of fluorescein-ifenprodil (10 mM, 15 min.); (C) merged image showing
co-localisation. Images (D)–(F) are as for (A)–(C) but with a pre-incubation
of ifenprodil (10 mM, 15 min.).39 Ds-Red is a red fluorescent protein.
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The targeting of metabotropic glutamate (mGluR5) receptors
by new MRI contrast agents has been reported.40 The contrast
agents were derived from a [Gd.DOTA] complex with fast water
exchange kinetics, linked via a glutarate arm to various selective
mGluR5 antagonists (Scheme 5).
Since appending a Gd(III) complex to an antagonist represents a
substantial modification to the chemical structure of the antagonist,
the antagonistic eﬀect of the modified contrast agents was investi-
gated. Based on changes in intracellular Ca2+ levels, only three of
the eight complexes examined, [Gd.L1.10], [Gd.L1.11] and [Gd.L1.12]
maintained a significant antagonistic eﬀect.7
A complete study of the concentration-dependence on the
cellular relaxation rate (R1,cell) enhancement of primary rat
astrocytes expressing mGluR5 receptors was undertaken, by
recording T1-weighted MR images at 3 Tesla. The complex
derived from the most potent antagonist, gave rise to the largest
enhancement in R1,cell (35% at 200 mM). However, this complex
did not exhibit any antagonist eﬀect and [Gd.L1.10] (R1,cell = 33%
at 200 mM) was identified as a lead compound from the alkyne-
based series of contrast agents. Of the dipyridyl amide systems,
[Gd.L1.12] exhibited the largest enhancement in R1,cell (30% at
200 mM) and possessed a significant antagonist eﬀect (Fig. 9).
Such behaviour was attributed to the antagonist moiety being
able to adopt a planar conformation, essential for mGluR5
aﬃnity.7
Following MR experiments, the cells treated with [Gd.L1.10] and
[Gd.L1.12] were subject to ICP-MS measurements to determine the
total Gd(III) content. Between 6 to 60  107 Gd(III) ions per cell were
present, which is well above the detection limit of modern MRI
experiments. However, the cellular relaxivities were found to diﬀer
substantially (2.9 mM1 s1 and 7.4 mM1 s1, for [Gd.L1.10]
and [Gd.L1.12], respectively), suggesting a diﬀerent mechanism
for R1,cell enhancement. The enhancement due to [Gd.L
1.10] can
be assigned to the huge increase in cell-associated Gd(III),
whereas [Gd.L1.12] induces a comparable enhancement with
only one third Gd(III) present. Such behaviour suggests that
[Gd.L1.12] induces R1,cell enhancement due to its higher aﬃnity
for the mGluR5 receptor.
7
Scheme 5 Structures of selected mGluR5 receptor-targeted contrast agents and putative mode of action, illustrating the relaxivity change as a function
of reversible binding of the Gd(III) contrast agent to the cell surface receptor.40,41
Fig. 9 Above: representative T1-weighted MR images (3 T) of 1 107 cells;
below: cellular relaxation rates, R1,cell, after treatment of primary rat
astrocytes with (A) [Gd.DOTA], (B) [Gd.L1.10] and (C) [Gd.L1.12] (50 to
200 mM, 45 min.).7
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The enhancements in relaxation rates were tentatively assigned to
an increase in the tR value of the complex upon receptor binding.
This behaviour is reflected in the ability of [Gd.L1.12] to bind
reversibly to cells possessing mGluR5 in the presence of glutamate,
when studied by fluorescence spectroscopy.40 Internalisation of the
contrast agents was ruled out by performing control experiments,
where competition assays in the presence of unmodified antagonists
resulted in no significant increase in relaxation rate. Furthermore,
derivatives of the lead compounds were synthesised that included a
remote biotin tag. These derivatives were shown to only label the
mGluR5 receptors located on the surface of primary rat astrocytes
using confocal and TIRF microscopy, after co-incubation with the
fluorescent avidin-Alexafluors-488 conjugate (Fig. 10).41
Similar work has been reported for NMDA receptors, in vitro and
in cellulo. The synthesis and behaviour of competitive NMDAR
antagonist conjugates has been reported, based on 3,4-diamino-3-
cyclobutene-1,2-diones developed by Kinney.42 The NMDA receptor
is a tetrameric complex, most commonly built up from alternating
GluN1 and GluN2 sub-units. These receptor-targeted moieties are
competitive antagonists that can bind to the GluN2 subunit where
the glutamate binding site is located.43 In initial work,40 immuno-
fluorescence staining experiments were undertaken and established
the presence of the GluN2B subunit. The targeting moieties based
on the competitive antagonist sub-unit were conjugated to modified
[Gd.DOTA] complexes that possess a single fast-exchanging water
molecule, (Scheme 6).
As water exchange is fast at Gd, the relaxivity in the low to
mid-field range (1 to 3 T), is dominated by rotational dynamics
and is sensitive to receptor binding.5,6 Initial studies in cell
suspensions of an NSC-34 cell line showed relaxation enhance-
ments of up to 75% on cell surface binding, versus control cells
lacking NMDA receptors or versus cells treated with non-targeted
[Gd.DOTA].44 The conjugates were non-toxic, consistent with
evidence from optical microscopy studies that revealed the
conjugate clearly binding to the cell surface receptors, with no
evidence for cell internalization. Furthermore, the confocal
microscopy studies with the biotin-labelled derivative estab-
lished both the specificity and the reversibility of probe binding,
in the absence and presence of added glutamate.44,45 Such an
approach augurs well for future studies in vivo, and further
strengthens the case to use competitive antagonists as targeting
vectors for the molecular imaging of cell-surface receptors.
However, with anionic complexes of this molecular volume the
blood brain barrier is not likely to be crossed. More immediate
applications are best directed to address basic neuroscience
investigations, as administration to the brain requires direct
injection into the brain parenchyma. Nevertheless, applications
beyond basic neuroscience can be envisaged, for example under
disease-based circumstances when the blood–brain barrier is
damaged or its permeability artificially enhanced.
4. Conclusions and future challenges
The design of a conjugate that can serve as an MR contrast agent
for a cell-surface receptormust consider several issues at the outset.
Fig. 10 (a) Total internal reflectance fluorescence (TIRF) and (b) confocal
microscopy images of primary rat astrocytes after incubation with a biotin
derivative of [Gd.L1.12] showing predominant cell surface localisation.
Green emission (avidin-AlexaFluors-488) indicates the labelled mGluR5
receptors; the orange emission shows total plasma membrane staining
and blue emission (Hoechst dye) highlights the nucleus.33
Scheme 6 MRI contrast agents targeted to the NMDA receptor on neurons.44,45
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The selection of the cell-surface receptor to target must be
undertaken judiciously. It should be present in suﬃciently high
abundance (i.e. a high receptor density) that cellular diﬀeren-
tiation of contrast agent binding can occur, by minimising the
degree of non-specific binding to other cell types. For several
receptor types, e.g. folate, fast internalisation of the contrast
agent is very likely to occur after receptor binding, if the
contrast agent design is based on the natural substrate, or
agonist. Such systems – like the putative ‘intracellular receptor
targeted’ contrast agents for progesterone receptors – raise
concerns for future use in humans, as the internalised con-
jugate is likely to be eventually trapped in an endosome or
lysosomal compartment, enhancing the chances of the long
term retention of the toxic gadolinium ion. Mechanisms that
increase the probability of the long-term retention of gadoli-
nium are best avoided, as the debilitating and potentially fatal
disease nephrogenic systemic fibrosis has been demonstrated
to be associated with Gd retention in humans with impaired
renal clearance. In these cases the contrast agent is circulating
in the body for a much longer period of time. In particular, the
use of Gd complexes and conjugates of DTPA-diamide ligands
are of concern, as these complexes are inherently less stable
with respect to acid-promoted dissociation of gadolinium,48
and have been shown to be more sensitive to metabolic
degradation in cells, compared to macrocyclic analogues.49
Due to the intrinsic insensitivity of MRI, it is often necessary to
establish or confirm the localisation profile of a Gd(III) complex
through direct visualisation using an alternative imaging technique.
Dual modality imaging agents are desirable for this purpose, but
care must be taken in the design of the final complex. The
structure of the parent complex must be minimally perturbed,
such that changes to the overall complex charge and hydropho-
bicity are minimized; such changes may radically aﬀect pharma-
cokinetics and pharmacodynamics. Simply appending a
secondary reporter group can drastically alter the localisation
profile of a receptor-targeted Gd complex, as was observed in the
case of certain luminescent analogues of a mGluR5-targeted
imaging agent, wherein probe localisation was determined by
an added lipophilic chromophore (that probably encouraged
non-specific uptake by macropinocytosis50) rather than by the
receptor-targeting moiety.41
By critically assessing recent progress in molecular imaging
for MRI, the following four main conclusions can be drawn in
designing a Gd based molecular imaging agent. First, the
gadolinium contrast agent should contain an MR-active core,
conjugated to a known ligand for the receptor, in which fast
water exchange occurs at Gd, such that tR, and not the rate of
water exchange at the metal centre, limits the relaxivity
enhancement that occurs on receptor binding. Such design
criteria will tend to maximise the change of relaxivity from the
unbound to the bound state.
Second, the incorporation of the contrast agent moiety into
the conjugate should cause little or no perturbation to the
aﬃnity and selectivity of receptor binding. Moreover, the use of
coordinatively unsaturated Gd centres should be avoided (e.g.
those based on heptadentate ligands), as this is likely to lead to
competitive and non-selective protein binding at the metal
centre, as well as displacement of the Gd-bound water.11
Third, the contrast agent should bind to the receptor in a
reversible manner and, where appropriate, with comparable
aﬃnity to the endogenous ligand. Such a situation arises for
glutamate receptors in neuronal cells, for example, as in the
mGluR5 and NMDA receptor types.
Finally, the targeting moiety may be better selected based on
known competitive antagonists, rather than mimic or copy the
structure of established agonists. In work with targeted SPECT
tumour imaging using 111In radiolabelled conjugates, those
based on somatostatin receptor antagonists were shown to be
superior to systems based on the natural agonist structure.46,47
In contrast to an agonist, a competitive antagonist usually
does not trigger receptor internalisation, following cell surface
receptor binding. Provided that suﬃcient signal contrast can be
obtained, such behaviour is arguably preferable as a strategy for
contrast agent design, as it reduces the risk of longer term retention
of the contrast agent andmay feature more strongly in future work.
Of course, each agent must be assessed carefully for its toxicity
profile, in cellulo and in vivo prior to any use in humans.
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